BPC-157: Published Research, Chemical Identity and Batch Documentation
BPC-157 is a synthetic 15-amino-acid peptide (C62H98N16O22, 1419.5 g/mol) studied mainly in rats and cultured cells. Published animal and cell studies have examined it in tendon, ligament and muscle injury models and in angiogenesis signaling. Vial & Error supplies BPC-157

Batch documentation
Every Vial & Error batch is held to a 98%+ purity floor and is backed by two separate records: the manufacturer COA and a third-party test from ACS Peptide Testing Labs. The current ACS result for BPC-157 is below.
| Batch tested | VE2026-bpc-001 |
|---|---|
| Laboratory | ACS Peptide Testing Labs |
| Accession number | AAHV635 |
| Purity (LCMS-UV) | 99.88% |
| Mass identification | BPC-157 |
| Reported | July 28, 2026 |
Results apply only to the sample the lab tested. View the COA and ACS report on the BPC-157 product page.
What is BPC-157? Chemical identity
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val [1] |
|---|---|
| CAS number | 137525-51-0 [PubChem] |
| Molecular formula | C62H98N16O22 [PubChem] |
| Molecular weight | 1419.5 g/mol (computed, free peptide) [PubChem] |
| PubChem CID | 9941957 [PubChem] |
Identity values from PubChem CID 9941957. Salt forms (for example acetate) have a higher molecular weight; the batch COA governs.
What have published studies on BPC-157 examined?
Before you read the table: every row describes an animal or in-vitro experiment, and the doses and concentrations are copied as published. They are literature reference only, not guidance, recommendations or protocols for any use.
| Model type | Model | Concentration or dose (as reported) | Route | Duration | Outcome (as reported) | Source |
|---|---|---|---|---|---|---|
| Animal + in vitro | Rat, transected Achilles tendon; cultured rat tendocytes | 10 µg, 10 ng or 10 pg/kg body weight, once daily (as reported) | Intraperitoneal | Assessed days 1–14 | Higher load of failure, Young's modulus and Achilles functional index vs saline controls; in culture, no growth effect alone but opposed 4-hydroxynonenal growth inhibition | Staresinic M 2003 [1] PMID 14554208 · DOI |
| Ex vivo / in vitro | Rat Achilles tendon explants and tendon fibroblasts | Not stated in abstract (dose-dependent design) | Culture medium | Not stated in abstract | Faster explant outgrowth; no direct effect on proliferation; higher survival under H2O2 stress; dose-dependent migration; increased FAK and paxillin phosphorylation | Chang CH 2011 [2] PMID 21030672 · DOI |
| In vitro | Rat Achilles tendon fibroblasts | Not stated in abstract (dose- and time-dependent design) | Culture medium | Not stated in abstract | Increased growth hormone receptor mRNA and protein; JAK2 activation when growth hormone was added | Chang CH 2014 [3] PMID 25415472 · DOI |
| Animal + in vitro | Chick chorioallantoic membrane; human vascular endothelial cells in culture; rat hind-limb ischemia | Not stated in abstract | Not stated in abstract | Not stated in abstract | Higher vessel density; faster blood-flow recovery in ischemic rat muscle; increased VEGFR2 expression and VEGFR2–Akt–eNOS activation | Hsieh MJ 2017 [4] PMID 27847966 · DOI |
| Animal | Rat, transected medial collateral ligament | 10 µg or 10 ng/kg once daily; 1.0 µg/g cream; 0.16 µg/mL in drinking water (as reported) | Intraperitoneal, topical, or oral (drinking water) | Up to 90 days | Functional, biomechanical, macroscopic and histological improvements vs controls | Cerovecki T 2010 [5] PMID 20225319 · DOI |
| Animal | Rat, gastrocnemius muscle crush injury | Not stated in abstract | Intraperitoneal or topical cream | Up to 14 days | Less hematoma and edema; improved microscopic, functional and enzyme measures vs controls | Novinscak T 2008 [6] PMID 18668315 · DOI |
| Animal (pharmacokinetics) | Rats and beagle dogs | Single IV dose; single IM doses at three levels; repeated IM (values not stated in abstract) | Intravenous, intramuscular | Single and repeated administration | Elimination half-life under 30 min; linear kinetics; IM bioavailability about 14–19% (rats) and 45–51% (dogs); excreted in urine and bile | He L 2022 [7] PMID 36588717 · DOI |
Anecdotal or calculation only. Not dosing guidance or medical advice. For laboratory research use only.
Values come from PubMed abstracts only. A cell reading "Not stated in abstract" means the figure appears only in the full paper, and we left it out rather than guess.
What mechanisms have been reported for BPC-157?
Each statement below is limited to what the cited rat, dog or cell-culture study reported.
- In cultured rat tendon fibroblasts, BPC-157 increased cell migration and the phosphorylation of FAK and paxillin without directly changing proliferation. [2]
- In rat tendon fibroblasts, BPC-157 increased growth hormone receptor expression at the mRNA and protein level. [3]
- In endothelial cells and a rat hind-limb ischemia model, BPC-157 was associated with increased VEGFR2 expression and activation of VEGFR2–Akt–eNOS signaling. [4]
- In rats and beagle dogs, intact BPC-157 had an elimination half-life under 30 minutes and was metabolized into small peptide fragments and amino acids. [7]
Storage notes for BPC-157 (supplier guidance)
Supplier guidance, unconfirmed: the supplier lists −20 °C, desiccated, for long-term storage and 2–8 °C for short-term storage, away from light. Let the vial reach room temperature before opening so condensation does not form.
This page cites no stability study for BPC-157, and nothing here establishes how stable a reconstituted solution is. Use your laboratory’s validated procedures.
Why researchers source BPC-157 from Vial & Error
- A published ACS Peptide Testing Labs report is on file.
- Two independent records back the 98%+ purity floor: the manufacturer COA and the ACS report.
- The study table cites primary papers, each with a PMID and DOI link.
Order BPC-157 with its COA on file
The BPC-157 product page carries the current COA section, along with ordering.
Review BPC-157 product details Send BPC-157 straight to checkout
Prefer to plan the solution first? Run the molarity numbers at 1419.5 g/mol before you order.
Frequently asked questions
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. PubChem lists its formula as C62H98N16O22 and its computed molecular weight as 1419.5 g/mol (CID 9941957).
What models has BPC-157 been studied in?
The studies in our table used rats, beagle dogs, chick chorioallantoic membrane, rat tendon explants and fibroblasts, and human vascular endothelial cell cultures. Each row is labeled as animal or in vitro.
What is the molecular weight of BPC-157 for molarity calculations?
PubChem lists 1419.5 g/mol for the free peptide. Salt forms such as acetate weigh more, so use the molecular weight on your batch COA when it differs.
Which BPC-157 batch was tested by ACS Peptide Testing Labs?
The current ACS Peptide Testing Labs report lists purity by LCMS-UV and mass identification for the sample tested. Results apply only to the sample the lab tested.
How should lyophilized BPC-157 be stored?
Supplier guidance, not yet confirmed against manufacturer stability data: desiccated at −20 °C for long-term storage and 2–8 °C for short-term storage, away from light.
Are the BPC-157 study doses guidance?
No. Concentrations and doses in the table are quoted from rat and cell experiments for literature reference. They are not guidance for any use, and BPC-157 from Vial & Error is
References
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PMID 14554208 · doi:10.1016/S0736-0266(03)00110-4
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID 21030672 · doi:10.1152/japplphysiol.00945.2010
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID 25415472 · doi:10.3390/molecules191119066
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID 27847966 · doi:10.1007/s00109-016-1488-y
- Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. PMID 20225319 · doi:10.1002/jor.21107
- Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008. PMID 18668315 · doi:10.1007/s00595-007-3706-2
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PMID 36588717 · doi:10.3389/fphar.2022.1026182
[PubChem] National Center for Biotechnology Information. PubChem Compound Summary, CID 9941957.